NasdaqGS:PCRXPharmaceuticals
How Investors May Respond To Pacira BioSciences (PCRX) Proxy Battle And New EXPAREL Real-World Data
In April 2026, Pacira BioSciences filed a preliminary proxy urging shareholders to support its three board nominees over those put forward by DOMA Perpetual Capital Management, while also presenting new real-world data at a major managed care pharmacy meeting showing EXPAREL’s economic and opioid-sparing profile in outpatient hip and knee replacements.
The combination of proxy contest developments and fresh health-economic evidence for EXPAREL’s use in high-volume joint procedures sharpens...